TSCAN THERAPEUTICS INC. - COMMON STOCK

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

17 أبريل 2024 00:30:57 بحسب Nasdaq GlobeNewswire

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

16 أبريل 2024 16:25:22 بحسب Nasdaq GlobeNewswire

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

16 أبريل 2024 16:01:00 بحسب Nasdaq GlobeNewswire

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer

08 أبريل 2024 08:00:00 بحسب Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

02 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

06 مارس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

28 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

26 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

14 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

06 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

29 يناير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

18 يناير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

04 يناير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

09 ديسمبر 2023 12:00:00 بحسب Nasdaq GlobeNewswire

TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations

07 ديسمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition

04 ديسمبر 2023 16:05:00 بحسب Nasdaq GlobeNewswire

TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer

04 ديسمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years

30 نوفمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

09 نوفمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting

06 نوفمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire